1161002-05-6
中文名称
G15;G-15;G 15;1161002-05-6
英文名称
(3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinoline
CAS
1161002-05-6
分子式
C19H16BrNO2
分子量
370.24
MOL 文件
1161002-05-6.mol
更新日期
2023/03/20 15:41:25

基本信息
中文别名
15国集团化合物G15
(3AS,4R,9BR)-4-(6-溴苯并[D][1,3]二恶英-5-基)-3A,4,5,9B-四氢-3H-环戊烷[C]喹啉
英文别名
H37G-15
RMB5
LUCA15
AGPAT1
1-AGPAT1
LPAAT-alpha
G15
G-15
G 15
1161002-05-6
RNA binding motif protein 5
Compound G15 - GPR30 antagonist
物理化学性质
熔点178-180 °C
沸点462.7±45.0 °C(Predicted)
密度1.472±0.06 g/cm3(Predicted)
储存条件-20°C储存
溶解度insoluble in H2O; insoluble in EtOH; ≥37 mg/mL in DMSO
酸度系数(pKa)3.98±0.40(Predicted)
形态固体
颜色White to off-white
生物来源rabbit
G-15,GPER拮抗剂价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-103449 | G-15,GPER拮抗剂 G15 | 1161002-05-6 | 1 mg | 323元 |
2025/02/08 | HY-103449 | G15;G-15;G 15;1161002-05-6 G15 | 1161002-05-6 | 5mg | 712元 |
2025/02/08 | HY-103449 | G15;G-15;G 15;1161002-05-6 G15 | 1161002-05-6 | 10mM * 1mLin DMSO | 783元 |
常见问题列表
生物活性
G15是一种高亲和力、选择性的G-protein coupled estrogen receptor 1 (GPER, GPR30) 拮抗剂,约20 nM的结合亲和力,在浓度高达10 μM时,对ERα和ERβ没有亲和力。靶点
Target | Value |
GPER
() |
体外研究
G15 (0.1-10 μM; 2 days) inhibits GPER-mediated proliferation stimulated by 17β-estradiol (E2) in A549 and H1793 cell lines.
G15 (1 μM; 48 hours) inhibits the response of GPER stimulated by E2 and G1 in A549 and H1793 cell lines.
Cell Proliferation Assay
Cell Line: | A549, H1793 cell lines |
Concentration: | 0.1, 1, 10 μM (combination with 10 nM E2) |
Incubation Time: | 2 days |
Result: | Inhibited GPER-mediated proliferation stimulated by E2. |
Western Blot Analysis
Cell Line: | A549, H1793 cell lines |
Concentration: | 1 μM (combination with 10 nM E2 and 10 nM G1) |
Incubation Time: | 48 hours |
Result: | Inhibited the response of GPER stimulated by E2 and G1. |
体内研究
G15 (1.46 mg/kg; i.h.; twice a week for 14 weeks) decreases the number of tumor nodules and tumor index increased by the E2 or G1 group in urethane-induced adenocarcinoma mice.
Animal Model: | Four-week-old female Kunming mice (Urethane-induced adenocarcinoma) |
Dosage: | 1.46 mg/kg (combination with E2, 0.09 mg/kg and fulvestrant (Ful), 2.4 mg/kg) |
Administration: | Subcutaneous injection; twice a week for 14 weeks |
Result: | The number of tumor nodules decreased in the E2+Ful+G15 group. |